MedPath

HoFH, the International Clinical Collaborators Registry

Recruiting
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Other: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Registration Number
NCT04815005
Lead Sponsor
University of Pennsylvania
Brief Summary

Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.

Detailed Description

The HICC registry is an observational, multicenter, international registry collecting de-identified clinical and genetic information from patients with homozygous Familial Hypercholesterolemia (HoFH) worldwide.

Patients are eligible to be enrolled in the registry based on the diagnosis of HoFH by the treating clinician, irrespective of how the diagnosis was made. To generate up-to-date data reflecting current rather than historic practice, patients who died or were lost to follow-up prior to 2010 are excluded.

Anonymized data on demographics, type of HoFH diagnosis (clinical and/or based on the results of a genetic test), genetic results, (cardiovascular) medical history, relevant family history, physical examination, laboratory measurements, lipid lowering treatment and cardiovascular imaging are collected for 3 different time points: at diagnosis, at enrolment and at time of best lipid profile (if this is different from time at enrolment). Data are collected using pre-definite electronic case report forms to ensure uniformity of data collected. Primary analysis will be cross-sectional (e.g. based on country of residence, age, etc)

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined
Read More
Exclusion Criteria
  • No diagnosis of HoFH
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
HoFHDemographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.
Primary Outcome Measures
NameTimeMethod
Number of participants entered into the databaseThrough study completion, an average of 8 years

Number of study participants with homozygous familial hypercholesterolemia

Secondary Outcome Measures
NameTimeMethod
Untreated and treated LDL-C levels across world income regionsThrough study completion, an average of 8 years

Number of treated versus number of untreated subjects with relevant LDL-C levels

Trial Locations

Locations (4)

c. Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand

πŸ‡ΏπŸ‡¦

Johannesburg, South Africa

Department of Vascular Medicine, Amsterdam UMC

πŸ‡³πŸ‡±

Amsterdam, Netherlands

University of Pennsylvania

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

Department of Medicine, Division of Lipidology and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town

πŸ‡ΏπŸ‡¦

Cape Town, South Africa

Β© Copyright 2025. All Rights Reserved by MedPath